banter and General Discussion, page-6895

Thank you again everyone for your input. Some of that deeper analysis has provided answers I had been looking for from the outset when I first posed a question centring on the licensed use of our product in Japan. Really I should thank DocMcstuffins because his unwavering contrarian position on all matters MSB generated more information during yesterdays exchange than I could ever have hoped for regarding how it is we just ignore what has been happening in Japan for years. The debate has been often factual (I never intended to precipitate the personal attacks), the facts eloquently presented and when stacked alongside the naysayers suite of arguments cause me to remain convinced this biotech is not only not going away, but fast marching toward mainstream standard of care treatment(s). Dachopper and Treed certainly bring some solid material to the debate and I think it is Lopez who reminds us that it is very difficult to ignore the commentary of a highly qualified medical specialist(s) with first hand experience treating patients for illness with the very cells we are seeking FDA approval for. I for one remain convinced I have backed the right horse and remain at a loss to understand how the share price can be where it is if you subscribe to the view our first FDA approval is imminent. If we get denied approval again, the FDA’s reasoning is sure going to make for an interesting read, because last time I get it given we are essentially gold standard if first over the line, but if the CRL issues were addressed (assuming the old another RCT chestnut doesn’t resurface) and manufacturing is in order, what is left? It works, it’s safe. Time will be our friend. I’m still buying, not selling.